Selected publications

Research papers

1. Kondrashova O, Topp Monique, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, Australian Ovarian Cancer Study, DeFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, SCOTT CL. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018 9(1):3970. PMID: 30266954
2. Kondrashova O*, Nguyen M*, Shield-Artin K*, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K*, SCOTT CL*. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017 Jun 6 PMID: 28588062. *equal contribution
3. Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, SCOTT CL. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017. 145(1):130-136. PMID: 28162234
4. Swisher EM*, Lin KK*, Oza AM, SCOTT CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O’Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinumsensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 18(1):75-87. PMID: 27908594 *equal contribution.
5. Topp M, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield M, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular Oncol 2014. 8(3):656-68. PMID: 24560445
6. Kerr JB^#, Hutt KJ^#, Michalak EM^#, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL *, Findlay JK*, Strasser A*. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require Tap63-mediated induction of Puma and Noxa. Mol Cell. 2012.;48(3):343-52. ^#joint first author, *joint senior author. Cover Image. PMID: 23000175

Review articles

1. Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA. Targeting DNA repair: the genome as a potential biomarker. J Pathol. 2018, 244(5): 586-597. PMID: 29282716
2. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: Recent advances and future developments. J Clin Oncol. 2015. 33(12):1397-406. PMID: 25779564
3. Lodhia K, Hadley H, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta. Rev on Cancer 2015. 1855(2):223-234. PMID: 25783201

Further publications

Book chapter

Gwo, H, Scott CL*, Pham K*.  “PDX models in cancer research and therapy around the world: Global practices in PDX programs” in “Patient Derived Tumor Xenograft Models: Promise, Potential and Practice”.  Elsevier. *Joint senior author. Published by Elsevier 1 Nov 2016. The first international survey of laboratories working with pre-clinical models (patient-derived xenografts or “PDX”).